Background: Equine insect bite hypersensitivity (IBH) is an immediate-type hypersensitivity reaction provoked by insect-derived allergens. Icelandic horses living in Iceland do not have IBH due to absence of relevant insects, but acquire it at high frequency after being imported to mainland Europe. In contrast, their offspring born in mainland Europe has reduced IBH incidence. T helper 1 (Th1) and Th2 cells and cytokines were determined in Icelandic horses born in Iceland and on the continent and which either have IBH or are healthy. Methods: Peripheral blood mononuclear cells (PBMC) from these horses were stimulated for 18 h dur- ing summer and winter with polyclonal T cell stimuli, IBH allergen(s) or irrelevant allergen(s). Cells were analysed by flow cytometry for interferon-γ (IFN-γ) and interleukin-4 (IL-4); RNA was analysed for IFN-γ, IL-4, IL-5 and IL-13 mRNA. Results: During summer, but not during winter, IBH PBMC stimulated polyclonally showed reduced IFN-γ mRNA and IFN-γ-producing cells when compared with those of healthy horses, regardless of origin. PBMC stimulated polyclonally or with IBH allergen showed increased IL-4 mRNA levels and higher numbers of IL-4-producing cells when born in Iceland or showing IBH symptoms. IL-5 and IL-13 mRNA were modulated neither by disease nor by origin. Abrogation of IL-4 production in healthy horses born in mainland Europe may be due, at least in part, to IL-10. There was an increased level of IL-10 in supernatants from PBMC of healthy horses born in mainland Europe and stimulated polyclonally or with IBH allergen. Conclusions: Modulation of IBH incidence is governed by altered Th1/Th2 ratio, which might be influenced by IL-10.

Keywords:
Interferon-γ, Interleukin-10, Interleukin-13, Interleukin-4, Interleukin-5, Immediate-type hypersensitivity, T helper cells, Horse, Icelandic, Insect bite hypersensitivity
1.
Prescott SL: Bacteria and the allergy epidemic: the culprits and the cure? Curr Allergy Clin Immunol 2004;17:108–114.
2.
Kay AB: Overview of ‘allergy and allergic diseases: with a view to the future’. Br Med Bull 2000;56:843–864.
3.
Ono SJ: Molecular genetics of allergic diseases. Annu Rev Immunol 2000;18:347–366.
4.
Piccinni MP, Maggi EN, Romagnani SE: Environmental factors favoring the allergen-specific Th2 response in allergic subjects. Ann NY Acad Sci 2000;917:844–852.
5.
von Ehrenstein OS, von Mutius E, Illi S, Baumann L, Bohm O, von Kries R: Reduced risk of hay fever and asthma among children of farmers. Clin Exp Allergy 2000;30:187–193.
6.
Hellberg W, Wilson AD, Mellor P, Doherr MG, Torsteinsdottir S, Zurbriggen A, Jungi T, Marti E: Equine insect bite hypersensitivity: immunoblot analysis of IgE and IgG subclass responses to Culicoides nubeculosus salivary gland extract. Vet Immunol Immunopathol 2006.
7.
Marti E, Urwyler A, Neuenschwander M, Eicher R, Meier D, de Weck AL, Gerber H, Lazary S, Dahinden CA: Sulfidoleukotriene generation from peripheral blood leukocytes of horses affected with insect bite dermal hypersensitivity. Vet Immunol Immunopathol 1999;71:307–320.
8.
van der Haegen A, Griot-Wenk M, Welle M, Busato A, von Tscharner C, Zurbriggen A, Marti E: Immunoglobulin-E-bearing cells in skin biopsies of horses with insect bite hypersensitivity. Equine Vet J 2001;33:699–706.
9.
Brostrom H, Larsson A, Troedsson M: Allergic dermatitis (sweet itch) of Icelandic horses in Sweden: an epidemiological study. Equine Vet J 1987;19:229–236.
10.
Halldordsottir S, Larsen HJ: An epidemiological study of summer eczema in Icelandic horses in Norway. Equine Vet J 1991;23:296–299.
11.
Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz G, Valenta R, Fiebig H, Kegel C, Disch R, Schmidt-Weber CB, Blaser K, Akdis CA: Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004;199:1567–1575.
12.
Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA: Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β: the role of T regulatory cells. Immunology 2006;117:433–442.
13.
Baselgia S, Doherr MG, Mellor P, Torsteinsdottir S, Jermann T, Zurbriggen A, Jungi T, Marti E: Evaluation of an in vitro sulphidoleukotriene release test for diagnosis of insect bite hypersensitivity in horses. Equine Vet J 2006;38:40–46.
14.
Bustin SA: Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000;25:169–193.
15.
Pedersen LG, Castelruiz Y, Jacobsen S, Aasted B: Identification of monoclonal antibodies that cross-react with cytokines from different animal species. Vet Immunol Immunopathol 2002;88:111–122.
16.
Kwong LS, Hope JC, Thom ML, Sopp P, Duggan S, Bembridge GP, Howard CJ: Development of an ELISA for bovine IL-10. Vet Immunol Immunopathol 2002;85:213–223.
17.
Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A: IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815–3822.
18.
Akdis CA, Joss A, Akdis M, Blaser K: Mechanism of IL-10-induced T cell inactivation in allergic inflammation and normal response to allergens. Int Arch Allergy Immunol 2001;124:180–182.
19.
Wilson AD, Harwood LJ, Bjornsdottir S, Marti E, Day MJ: Detection of IgG and IgE serum antibodies to Culicoides salivary gland antigens in horses with insect dermal hypersensitivity (sweet itch). Equine Vet J 2001;33:707–713.
20.
Savolainen J, Laaksonen K, Rantio-Lehtimaki A, Terho EO: Increased expression of allergen-induced in vitro interleukin-10 and interleukin-18 mRNA in peripheral blood mononuclear cells of allergic rhinitis patients after specific immunotherapy. Clin Exp Allergy 2004;34:413–419.
21.
Oral HB, Kotenko SV, Yilmaz M, Mani O, Zumkehr J, Blaser K, Akdis CA, Akdis M: Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26. Eur J Immunol 2006;36:380–388.
22.
Nuttall TJ, Knight PA, McAleese SM, Lamb JR, Hill PB: T-helper 1, T-helper 2 and immunosuppressive cytokines in canine atopic dermatitis. Vet Immunol Immunopathol 2002;87:379–384.
23.
Li MC, He SH: IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 2004;10:620–625.
24.
Dunstan JA, Hale J, Breckler L, Lehmann H, Weston S, Richmond P, Prescott SL: Atopic dermatitis in young children is associated with impaired interleukin-10 and interferon-γ responses to allergens, vaccines and colonizing skin and gut bacteria. Clin Exp Allergy 2005;35:1309–1317.
25.
Koning H, Neijens HJ, Baert MR, Oranje AP, Savelkoul HF: T cells subsets and cytokines in allergic and non-allergic children. II. Analysis and IL-5 and IL-10 mRNA expression and protein production. Cytokine 1997;9:416–426.
26.
van der Velden VH, Laan MP, Baert MR, de Waal Malefyt R, Neijens HJ, Savelkoul HF: Selective development of a strong Th2 cytokine profile in high-risk children who develop atopy: risk factors and regulatory role of IFN-γ, IL-4 and IL-10. Clin Exp Allergy 2001;31:997–1006.
27.
Jenmalm MC, Bjorksten B: Cord blood levels of immunoglobulin G subclass antibodies to food and inhalant allergens in relation to maternal atopy and the development of atopic disease during the first 8 years of life. Clin Exp Allergy 2000;30:34–40.
28.
Schiessl B, Zemann B, Hodgin-Pickart LA, de Weck AL, Griot-Wenk M, Mayer P, Nefzger M, Schneider H, Liehl E: Importance of early allergen contact for the development of a sustained immunoglobulin E response in a dog model. Int Arch Allergy Immunol 2003;130:125–134.
29.
Ainsworth DM, Appleton JA, Eicker SW, Luce R, Julia Flaminio M, Antczak DF: The effect of strenuous exercise on mRNA concentrations of interleukin-12, interferon-γ and interleukin-4 in equine pulmonary and peripheral blood mononuclear cells. Vet Immunol Immunopathol 2006;91:61–71.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.